{"gene":"HAS1","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2000,"finding":"HAS1 protein alone is sufficient to synthesize hyaluronan in vitro from UDP-GlcNAc and UDP-GlcA substrates, and when incubated with UDP-GlcNAc alone synthesizes chito-oligosaccharides. Site-directed mutagenesis of the cytoplasmic central loop domain identified specific amino acid residues essential for hyaluronan synthesis (both GlcNAc and GlcA transfer steps) and separate residues exclusively required for GlcA transfer but dispensable for chito-oligosaccharide synthesis, demonstrating that distinct residues mediate each sugar transfer reaction.","method":"Recombinant FLAG-tagged HAS1 purification from COS-1 membranes by anti-FLAG affinity chromatography; in vitro enzymatic assay with UDP-sugars; site-directed mutagenesis of cytoplasmic central loop domain; reconstitutive assay conditions","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted single-protein in vitro activity, combined with mutagenesis identifying catalytic residues in one rigorous study","pmids":["10617644"],"is_preprint":false},{"year":2013,"finding":"HAS1 requires substantially higher cellular UDP-GlcNAc concentrations than HAS2 or HAS3 to synthesize hyaluronan. In COS-1 cells with normal UDP-sugar levels, HAS1 is nearly inactive; supplementing with glucosamine (~10-fold increase in UDP-GlcNAc) rescues HAS1-driven hyaluronan synthesis and pericellular coat formation. HAS3 can produce hyaluronan at high speed even at minimal substrate concentrations.","method":"Transfection of human HAS1-3 isoenzymes into COS-1 cells; glucosamine and glucose manipulation to alter UDP-sugar pools; measurement of secreted hyaluronan by ELISA; pericellular coat detection by fluorescent hyaluronan-binding probe; HPLC quantification of UDP-sugars","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (metabolic manipulation, HA quantification, UDP-sugar measurement) in single rigorous study with clear isoenzyme comparisons","pmids":["23303191"],"is_preprint":false},{"year":2015,"finding":"HAS1, HAS2, and HAS3 form homomeric and heteromeric complexes with each other in live cells, detectable in both the Golgi apparatus and plasma membrane. Interactions occur primarily via an N-terminal ~86 amino acid domain, with additional C-terminal binding sites. HAS1 homomeric complexes have the lowest synthetic activity of all HAS complexes. HAS1 transfection reduces hyaluronan synthesis driven by HAS2 and HAS3, indicating that HAS1-containing heteromers functionally suppress overall HA synthesis.","method":"FRET with flow cytometric quantification in live cells; FRET microscopy with acceptor photobleaching; proximity ligation assay (PLA) with endogenous HAS antibodies; C-terminal deletion constructs to map interaction domains","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (FRET, PLA with endogenous proteins, deletion mapping, functional HA synthesis assay) in single study","pmids":["25795779"],"is_preprint":false},{"year":2013,"finding":"HAS1-produced hyaluronan coat on MCF-7 cells depends on CD44 for retention at the cell surface (unlike HAS3, whose coat remains attached to HAS3 itself). HAS1 enzymatic activity requires ER-Golgi-plasma membrane trafficking. The HAS1-dependent coat is induced by inflammatory cytokines (IL-1β, TNF-α, TGF-β) and high glucose/glucosamine, revealing context-dependent activation.","method":"Immunocytochemistry; transfection of fluorescently tagged HAS1; fluorescent hyaluronan-binding probe for coat detection; displacement with HA hexasaccharides and Hermes1 (anti-CD44) antibody; cytokine and glucose/glucosamine treatments","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization and functional displacement experiments, single lab, two orthogonal approaches","pmids":["24099991"],"is_preprint":false},{"year":2003,"finding":"HAS1 mRNA transcription in fibroblast-like synoviocytes is not constitutively active but is specifically induced by TGF-β and IL-1β. Hydrocortisone suppresses IL-1β-induced HAS1 activation by blocking TGF-β-induced phosphorylation of p38 MAPK, a kinase essential for HAS1 induction. HAS2 and HAS3 are constitutively expressed and are also suppressed by glucocorticoids, but via p38-independent mechanisms.","method":"RT-PCR for HAS mRNA levels in fibroblast-like synoviocytes; Western blot for p38 MAPK phosphorylation; glucocorticoid (hydrocortisone and dexamethasone) dose-response experiments","journal":"Rheumatology (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Western blot for signaling pathway + mRNA quantification, single lab, two orthogonal methods","pmids":["13130151"],"is_preprint":false},{"year":2005,"finding":"IL-1β induces HAS1 transcription via the NF-κB pathway (IκBα degradation and phosphorylation, NF-κB translocation), while TGF-β1 induces HAS1 transcription independently of NF-κB and IKK (TGF-β1 neither caused IκBα degradation nor NF-κB translocation). Overexpression of dominant-negative IKK or IκBα completely abolished IL-1β-induced HAS1 activation but did not affect TGF-β1-induced HAS1 or affect HAS2/HAS3 levels, demonstrating that HAS1 can be activated by two distinct upstream pathways.","method":"Adenovirus-mediated gene transfer of mutated IKK and IκBα constructs; RT-PCR for HAS mRNA; Western blot for IκBα phosphorylation/degradation; EMSA for NF-κB translocation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via dominant-negative constructs combined with multiple orthogonal methods (EMSA, Western blot, RT-PCR) establishing two independent pathway inputs to HAS1 transcription","pmids":["16258173"],"is_preprint":false},{"year":2005,"finding":"IL-1β-induced HAS1 transcription in fibroblast-like synoviocytes depends on tyrosine kinase activity (not NF-κB alone): leflunomide specifically blocked IL-1β-induced HAS1 induction and HA synthase activity without affecting constitutive HAS2/HAS3 expression, and two tyrosine kinase inhibitors replicated this selective HAS1 blockade. NF-κB inhibition by leflunomide was ruled out as the mechanism at concentrations that block HAS1.","method":"RT-PCR for HAS mRNAs; 14C-glucuronic acid incorporation assay for HAS enzymatic activity; EMSA for NF-κB translocation; tyrosine kinase inhibitor treatment; pyrimidine rescue experiments","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity assay combined with EMSA and pharmacological dissection, single lab","pmids":["15905585"],"is_preprint":false},{"year":2006,"finding":"NF-κB is required for IL-1β-induced HAS1 transcription in type-B synoviocytes: the NF-κB inhibitor PDTC completely abolished IL-1β-induced HAS1 mRNA accumulation and simultaneously blocked IκBα degradation and NF-κB translocation. This confirms HAS1 as an NF-κB-dependent gene in this cell type.","method":"RT-PCR for HAS1 mRNA; Western blot for IκBα; EMSA for NF-κB DNA binding; PDTC dose-response treatment in type-B synoviocytes","journal":"Experimental gerontology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA, Western blot, and RT-PCR used together, single lab, corroborates the NF-κB dependence established by paper 16258173","pmids":["16723203"],"is_preprint":false},{"year":2008,"finding":"Epstein-Barr virus and homopolymeric polycytidylic RNA analogs selectively induce HAS1 mRNA expression and HA release in fibroblast-like synoviocytes, while HAS2 and HAS3 remain unchanged. Virus-induced HAS1 activation requires both the p38 MAPK pathway and NF-κB: chemical MAPK inhibitors and overexpression of mutated IKK/IκBα each blocked virus-induced HAS1 transcription.","method":"Real-time RT-PCR; HA ELISA; chemical inhibitors of MAPK; adenovirus-mediated overexpression of mutated IKK and IκBα; treatment with live EBV and synthetic RNA polynucleotides","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (dominant-negative constructs) plus pharmacological dissection in single lab, consistent with prior mechanistic work","pmids":["18815290"],"is_preprint":false},{"year":2009,"finding":"HAS1 splice variants (Va, Vb, Vc) are concentrated in the cytoplasm and Golgi, unlike full-length HAS1 (FL) which is diffusely distributed. HAS1 splice variants synthesize hyaluronan intracellularly. When co-expressed, HAS1 variants physically interact with HAS1-FL (and with each other) to form heteromeric multiprotein assemblies, relocalize HAS1-FL from diffuse cytoskeletal locations to deeper cytoplasmic compartments, and protect HAS1-FL from its otherwise rapid turnover. HAS1-Vc alone is transforming in vitro and tumorigenic in vivo.","method":"Co-transfection with fluorescently tagged constructs; immunofluorescence/confocal microscopy for localization; co-immunoprecipitation for protein–protein interactions; pulse-chase for protein turnover; in vitro transformation assay; in vivo xenograft tumor formation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, localization imaging, and functional assays (transformation, in vivo tumor), single lab, multiple orthogonal methods","pmids":["19451652"],"is_preprint":false},{"year":2013,"finding":"Genetic variations introduced into introns 3 and 4 of a HAS1 minigene promote aberrant pre-mRNA splicing (intron retention and exon skipping) mimicking the pattern seen in multiple myeloma patients. Combining intron 4 deletion with intron 3 mutations shifts splicing from HAS1Vd to HAS1Vb, the clinically significant variant. Most MM patients harbor genetic variations in intron 4, and ~half in intron 3, confirming that intronic mutations drive aberrant HAS1 splicing.","method":"HAS1 minigene constructs with introduced deletions/mutations; in vitro splicing assay; sequencing comparison of transfectants vs. MM patient samples","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro splicing assay with defined mutagenesis, validated against patient samples, single lab","pmids":["23301075"],"is_preprint":false},{"year":2015,"finding":"Genetic deletion of Has1 in mice leads to chronic joint inflammation and widespread intra-articular fibrosis after cartilage injury, with persistent elevation of genes linked to ECM turnover, IL-17/IL-6 cytokine signaling, and apoptosis at 4 weeks post-injury (when wild-type mice show resolution). Notably, Has1 ablation does not alter gross HA content in ECM, indicating HAS1 has a unique function in regulating inflammatory HA matrices that is distinct from bulk HA production.","method":"Has1-/- mouse model; femoral groove cartilage debridement; histology, macroscopic imaging, and gene expression analysis at multiple timepoints; comparison with WT mice","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with specific phenotypic readout and gene expression profiling, single lab","pmids":["26521733"],"is_preprint":false},{"year":2024,"finding":"Phosphorylated tau (p-tau) mediates AβPP-induced cytosolic-to-nuclear translocation of HAS1. p-tau negatively regulates HAS1 stability, monoubiquitination, and oligomerization, thereby reducing HA synthesis and release. Non-ubiquitinated HAS1 loses enzymatic activity and translocates into the nucleus where it forms nuclear speckles, suggesting a non-canonical nuclear function in gene transcription regulation.","method":"Transcriptomic database screening; AβPP/PS1 mouse model validation; immunofluorescence for HAS1 localization; co-localization with nuclear speckle markers (SRRM2); HAS1 ubiquitination mutant analysis; HA ELISA; transcriptomic analysis of DEGs related to non-ubiquitinated HAS1","journal":"Matrix biology : journal of the International Society for Matrix Biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — abstract describes multiple findings but methods details are compressed; single lab, mechanistic chain (p-tau → HAS1 ubiquitination/localization) requires further validation","pmids":["38518923"],"is_preprint":false},{"year":2020,"finding":"STAT3 binds to the HAS1 promoter and positively regulates HAS1 expression; miR-125a suppresses STAT3 (a direct miR-125a target confirmed by dual-luciferase reporter), thereby reducing HAS1 mRNA and protein levels and suppressing NSCLC cell invasion and migration.","method":"Dual-luciferase reporter assay for miR-125a/STAT3 targeting; chromatin immunoprecipitation (ChIP) for STAT3 binding to HAS1 promoter; RT-qPCR and Western blot for STAT3 and HAS1; STAT3 overexpression; functional invasion/migration assays","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase assays are orthogonal methods establishing STAT3 as a direct transcriptional activator of HAS1, single lab","pmids":["31930562"],"is_preprint":false},{"year":2026,"finding":"HAS1 physically interacts with AMPK to form a complex, and disruption of this AMPK/HAS1 complex by elemicin ameliorates MASH. Loss-of-function of Has1 in liver reduces hepatic steatosis, inflammation, and fibrosis. Has1-mediated lipid metabolism is correlated with MASH severity.","method":"Co-immunoprecipitation (Co-IP); surface plasmon resonance (SPR); CETSA (cellular thermal shift assay); liver-specific Has1 inhibition in HFHC diet MASH mouse model; transcriptomic and lipidomic analyses; Western blotting","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, SPR, and CETSA for physical interaction, combined with in vivo loss-of-function, single lab","pmids":["41695466"],"is_preprint":false}],"current_model":"HAS1 is a plasma membrane-resident hyaluronan synthase that alone is sufficient to polymerize hyaluronan from UDP-GlcNAc and UDP-GlcA, with distinct cytoplasmic central loop residues mediating each sugar-transfer reaction; it has the highest substrate Km among the three HAS isoenzymes and is nearly inactive at normal cellular UDP-GlcNAc levels, forms homo- and heteromeric complexes with HAS2 and HAS3 (suppressing overall HA synthesis when complexed), is transcriptionally activated by IL-1β via NF-κB and by TGF-β via an NF-κB-independent/tyrosine kinase-dependent pathway (both requiring p38 MAPK in viral contexts), produces a CD44-anchored pericellular HA coat induced by inflammatory cytokines and metabolic stress, and in cancer settings undergoes aberrant intronic splicing driven by somatic intron mutations that generate dominant variant proteins which relocalize and stabilize full-length HAS1, synthesize intracellular HA, and are oncogenic; additionally, HAS1 physically interacts with AMPK and, in an Alzheimer's disease context, undergoes p-tau-regulated monoubiquitination and nuclear translocation where it influences gene transcription."},"narrative":{"mechanistic_narrative":"HAS1 is a plasma membrane-resident hyaluronan synthase that polymerizes hyaluronan from UDP-GlcNAc and UDP-GlcA, and is alone sufficient for synthesis: reconstituted FLAG-tagged enzyme builds HA in vitro and, with UDP-GlcNAc only, chito-oligosaccharides, with distinct cytoplasmic central-loop residues mediating each sugar-transfer step [PMID:10617644]. Among the three HAS isoenzymes it has the highest substrate requirement, being nearly inactive at normal UDP-GlcNAc levels and rescued only when the UDP-GlcNAc pool is raised by glucosamine [PMID:23303191]. HAS1 assembles into homo- and heteromeric complexes with HAS2 and HAS3 via an N-terminal domain, and HAS1-containing complexes have the lowest synthetic output, so HAS1 functionally suppresses overall HA synthesis [PMID:25795779]. Its enzymatic output requires ER-Golgi-plasma membrane trafficking and produces a CD44-anchored pericellular HA coat that is induced by inflammatory cytokines and high glucose/glucosamine [PMID:24099991]. HAS1 is an inducible rather than constitutive gene, transcriptionally activated by IL-1β through an NF-κB- and tyrosine-kinase-dependent route and by TGF-β through an NF-κB-independent, p38 MAPK-dependent route [PMID:13130151, PMID:16258173], and is also a direct STAT3 target [PMID:31930562]. In cancer, somatic intronic mutations drive aberrant HAS1 splicing into variants that relocalize and stabilize full-length HAS1, synthesize intracellular HA, and are oncogenic [PMID:19451652, PMID:23301075]. In vivo, Has1 loss causes chronic joint inflammation and intra-articular fibrosis without altering bulk ECM HA, indicating a specialized role in regulating inflammatory HA matrices [PMID:26521733].","teleology":[{"year":2000,"claim":"Establishing whether HAS1 is itself the catalytic synthase resolved whether a single protein performs the full dual-sugar polymerization reaction.","evidence":"Purified recombinant FLAG-HAS1 in vitro enzymatic assay with UDP-sugars plus central-loop site-directed mutagenesis","pmids":["10617644"],"confidence":"High","gaps":["No structure of the catalytic central loop","Mechanism of processive chain elongation and membrane translocation not resolved"]},{"year":2005,"claim":"Dissecting the upstream signaling inputs showed HAS1 is an inducible gene controlled by two independent transcriptional pathways rather than constitutive expression.","evidence":"Dominant-negative IKK/IκBα adenoviral epistasis, EMSA, RT-PCR, and tyrosine kinase inhibitor dissection in fibroblast-like synoviocytes (also #4, #6, #7, #8)","pmids":["16258173","13130151","15905585","16723203","18815290"],"confidence":"High","gaps":["Direct NF-κB and TGF-β-responsive elements in the HAS1 promoter not mapped","How tyrosine kinase signaling converges on HAS1 transcription unresolved"]},{"year":2009,"claim":"Characterizing HAS1 splice variants explained how aberrant HAS1 becomes oncogenic by relocalizing and stabilizing the full-length enzyme and producing intracellular HA.","evidence":"Co-transfection imaging, co-IP, pulse-chase turnover, in vitro transformation, and xenograft assays (also #10 minigene splicing)","pmids":["19451652","23301075"],"confidence":"Medium","gaps":["Splicing factors driving the intronic-mutation-dependent shift not identified","Mechanism by which intracellular HA promotes transformation unknown"]},{"year":2013,"claim":"Comparing isoenzyme kinetics and coat retention defined HAS1's distinctive low-activity, substrate-limited, CD44-dependent behavior relative to HAS2/HAS3.","evidence":"Isoenzyme transfection into COS-1 cells with UDP-sugar manipulation, HA ELISA, and CD44-antibody coat displacement (also #2 complex formation)","pmids":["23303191","24099991","25795779"],"confidence":"High","gaps":["Physiological conditions under which HAS1 reaches active UDP-GlcNAc thresholds in vivo unclear","Structural basis for the suppressive effect of HAS1 heteromers not defined"]},{"year":2015,"claim":"Genetic ablation in mice separated HAS1's role in inflammatory HA matrices from bulk HA production.","evidence":"Has1-/- mice with cartilage injury, histology, and gene-expression profiling","pmids":["26521733"],"confidence":"Medium","gaps":["Cellular source of the inflammatory HA matrix not pinpointed","Link to IL-17/IL-6 signaling correlative, not mechanistic"]},{"year":2024,"claim":"An Alzheimer's-context study proposed a non-canonical nuclear function for HAS1 regulated by p-tau-dependent monoubiquitination.","evidence":"AβPP/PS1 mouse validation, immunofluorescence, nuclear speckle co-localization, ubiquitination-mutant analysis, and HA ELISA","pmids":["38518923"],"confidence":"Low","gaps":["Mechanistic chain (p-tau → ubiquitination → nuclear translocation) requires independent validation","Direct transcriptional targets of nuclear HAS1 not established","Ubiquitin ligase responsible unidentified"]},{"year":2026,"claim":"Identification of an AMPK/HAS1 complex implicated HAS1 in hepatic lipid metabolism and metabolic liver disease.","evidence":"Reciprocal Co-IP, SPR, CETSA, and liver-specific Has1 loss-of-function in an HFHC MASH mouse model","pmids":["41695466"],"confidence":"Medium","gaps":["How AMPK binding modulates HAS1 catalysis or vice versa unresolved","Single lab; reciprocal in-cell consequence of complex disruption needs broader validation"]},{"year":null,"claim":"How HAS1's enzymatic activity, its suppressive heteromerization, and its non-canonical nuclear/metabolic functions are coordinated in a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model integrating catalysis, complex formation, and trafficking","Physiological switch between membrane synthase and nuclear/regulatory roles unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[2,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[12]}],"pathway":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0]}],"complexes":[],"partners":["HAS2","HAS3","CD44","AMPK"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q92839","full_name":"Hyaluronan synthase 1","aliases":["Hyaluronate synthase 1","Hyaluronic acid synthase 1","HA synthase 1","HuHAS1"],"length_aa":577,"mass_kda":64.7,"function":"Catalyzes the addition of GlcNAc or GlcUA monosaccharides to the nascent hyaluronan polymer. Therefore, it is essential for the synthesis of hyaluronan, a major component of most extracellular matrices that has a structural role in tissue architecture and regulates cell adhesion, migration and differentiation. This is one of the isozymes catalyzing that reaction. Also able to catalyze the synthesis of chito-oligosaccharide depending on the substrate (By similarity)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q92839/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HAS1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HAS1","total_profiled":1310},"omim":[{"mim_id":"602428","title":"HYALURONAN SYNTHASE 3; HAS3","url":"https://www.omim.org/entry/602428"},{"mim_id":"601636","title":"HYALURONAN SYNTHASE 2; HAS2","url":"https://www.omim.org/entry/601636"},{"mim_id":"601463","title":"HYALURONAN SYNTHASE 1; HAS1","url":"https://www.omim.org/entry/601463"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":46.2},{"tissue":"ovary","ntpm":19.3}],"url":"https://www.proteinatlas.org/search/HAS1"},"hgnc":{"alias_symbol":[],"prev_symbol":["HAS"]},"alphafold":{"accession":"Q92839","domains":[{"cath_id":"3.90.550.10","chopping":"96-168_193-396","consensus_level":"medium","plddt":95.6638,"start":96,"end":396}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92839","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92839-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92839-F1-predicted_aligned_error_v6.png","plddt_mean":88.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HAS1","jax_strain_url":"https://www.jax.org/strain/search?query=HAS1"},"sequence":{"accession":"Q92839","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92839.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92839/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92839"}},"corpus_meta":[{"pmid":"24337597","id":"PMC_24337597","title":"Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival.","date":"2013","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/24337597","citation_count":115,"is_preprint":false},{"pmid":"10617644","id":"PMC_10617644","title":"In vitro synthesis of hyaluronan by a single protein derived from mouse HAS1 gene and characterization of amino acid residues essential for the activity.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10617644","citation_count":101,"is_preprint":false},{"pmid":"23303191","id":"PMC_23303191","title":"Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23303191","citation_count":97,"is_preprint":false},{"pmid":"22785117","id":"PMC_22785117","title":"Hyaluronic acid, HAS1, and HAS2 are significantly upregulated during muscle hypertrophy.","date":"2012","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22785117","citation_count":63,"is_preprint":false},{"pmid":"20875124","id":"PMC_20875124","title":"Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20875124","citation_count":55,"is_preprint":false},{"pmid":"15731173","id":"PMC_15731173","title":"Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15731173","citation_count":54,"is_preprint":false},{"pmid":"12239172","id":"PMC_12239172","title":"Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12239172","citation_count":53,"is_preprint":false},{"pmid":"23788678","id":"PMC_23788678","title":"Has1 regulates consecutive maturation and processing steps for assembly of 60S ribosomal subunits.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23788678","citation_count":51,"is_preprint":false},{"pmid":"24406795","id":"PMC_24406795","title":"Extensive CD44-dependent hyaluronan coats on human bone marrow-derived mesenchymal stem cells produced by hyaluronan synthases HAS1, HAS2 and HAS3.","date":"2014","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24406795","citation_count":50,"is_preprint":false},{"pmid":"19435493","id":"PMC_19435493","title":"Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19435493","citation_count":49,"is_preprint":false},{"pmid":"26521733","id":"PMC_26521733","title":"Deficiency of hyaluronan synthase 1 (Has1) results in chronic joint inflammation and widespread intra-articular fibrosis in a murine model of knee joint cartilage damage.","date":"2015","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/26521733","citation_count":42,"is_preprint":false},{"pmid":"17230515","id":"PMC_17230515","title":"HAS1 expression in bladder cancer and its relation to urinary HA test.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17230515","citation_count":41,"is_preprint":false},{"pmid":"23645665","id":"PMC_23645665","title":"Low dose ultraviolet B irradiation increases hyaluronan synthesis in epidermal keratinocytes via sequential induction of hyaluronan synthases Has1-3 mediated by p38 and Ca2+/calmodulin-dependent protein kinase II (CaMKII) signaling.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23645665","citation_count":38,"is_preprint":false},{"pmid":"25795779","id":"PMC_25795779","title":"Fluorescence resonance energy transfer (FRET) and proximity ligation assays reveal functionally relevant homo- and heteromeric complexes among hyaluronan synthases HAS1, HAS2, and HAS3.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25795779","citation_count":36,"is_preprint":false},{"pmid":"24099991","id":"PMC_24099991","title":"Hyaluronan synthase 1 (HAS1) produces a cytokine-and glucose-inducible, CD44-dependent cell surface coat.","date":"2013","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/24099991","citation_count":31,"is_preprint":false},{"pmid":"15246064","id":"PMC_15246064","title":"Light and metabolic regulation of HAS1, HAS1.1 and HAS2, three asparagine synthetase genes in Helianthus annuus.","date":"2004","source":"Plant physiology and biochemistry : PPB","url":"https://pubmed.ncbi.nlm.nih.gov/15246064","citation_count":30,"is_preprint":false},{"pmid":"13130151","id":"PMC_13130151","title":"Glucocorticoids inhibit induced and non-induced mRNA accumulation of genes encoding hyaluronan synthases (HAS): hydrocortisone inhibits HAS1 activation by blocking the p38 mitogen-activated protein kinase signalling pathway.","date":"2003","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/13130151","citation_count":26,"is_preprint":false},{"pmid":"19451652","id":"PMC_19451652","title":"Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19451652","citation_count":24,"is_preprint":false},{"pmid":"18815290","id":"PMC_18815290","title":"Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18815290","citation_count":21,"is_preprint":false},{"pmid":"33908161","id":"PMC_33908161","title":"Hyaluronic acid (HA) stimulates the in vitro expression of CD44 proteins but not HAS1 proteins in normal human epidermal keratinocytes (NHEKs) and is HA molecular weight dependent.","date":"2021","source":"Journal of cosmetic dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/33908161","citation_count":19,"is_preprint":false},{"pmid":"15905585","id":"PMC_15905585","title":"Effects of leflunomide on hyaluronan synthases (HAS): NF-kappa B-independent suppression of IL-1-induced HAS1 transcription by leflunomide.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15905585","citation_count":19,"is_preprint":false},{"pmid":"23149717","id":"PMC_23149717","title":"Lentiviral-mediated over-expression of hyaluronan synthase-1 (HAS-1) decreases the cellular inflammatory response and results in regenerative wound repair.","date":"2012","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/23149717","citation_count":18,"is_preprint":false},{"pmid":"16723203","id":"PMC_16723203","title":"The NF-kappaB inhibitor pyrrolidine dithiocarbamate blocks IL-1beta induced hyaluronan synthase 1 (HAS1) mRNA transcription, pointing at NF-kappaB dependence of the gene HAS1.","date":"2006","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/16723203","citation_count":17,"is_preprint":false},{"pmid":"16258173","id":"PMC_16258173","title":"Adenovirus-mediated gene transfer of mutated IkappaB kinase and IkappaBalpha reveal NF-kappaB-dependent as well as NF-kappaB-independent pathways of HAS1 activation.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16258173","citation_count":16,"is_preprint":false},{"pmid":"17085450","id":"PMC_17085450","title":"The anti-rheumatic gold salt aurothiomalate suppresses interleukin-1beta-induced hyaluronan accumulation by blocking HAS1 transcription and by acting as a COX-2 transcriptional repressor.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17085450","citation_count":16,"is_preprint":false},{"pmid":"31930562","id":"PMC_31930562","title":"miR-125a regulates HAS1 and inhibits the proliferation, invasion and metastasis by targeting STAT3 in non-small cell lung cancer cells.","date":"2020","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31930562","citation_count":13,"is_preprint":false},{"pmid":"31511893","id":"PMC_31511893","title":"At least two molecules of the RNA helicase Has1 are simultaneously present in pre-ribosomes during ribosome biogenesis.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31511893","citation_count":10,"is_preprint":false},{"pmid":"23301075","id":"PMC_23301075","title":"Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23301075","citation_count":8,"is_preprint":false},{"pmid":"18400745","id":"PMC_18400745","title":"Hyaluronan production in synoviocytes as a consequence of viral infections: HAS1 activation by Epstein-Barr virus and synthetic double- and single-stranded viral RNA analogs.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18400745","citation_count":7,"is_preprint":false},{"pmid":"38518923","id":"PMC_38518923","title":"AβPP-tau-HAS1 axis trigger HAS1-related nuclear speckles and gene transcription in Alzheimer's disease.","date":"2024","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38518923","citation_count":6,"is_preprint":false},{"pmid":"25421996","id":"PMC_25421996","title":"Altered expression of hyaluronan, HAS1-2, and HYAL1-2 in oral lichen planus.","date":"2014","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25421996","citation_count":5,"is_preprint":false},{"pmid":"40813707","id":"PMC_40813707","title":"HAS1high cancer associated fibroblasts located at the tumor invasion front zone promote oral squamous cell carcinoma invasion via ECM remodeling.","date":"2025","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/40813707","citation_count":4,"is_preprint":false},{"pmid":"38862513","id":"PMC_38862513","title":"Whole-genome sequencing identifies variants in ANK1, LRRN1, HAS1, and other genes and regulatory regions for stroke in type 1 diabetes.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38862513","citation_count":3,"is_preprint":false},{"pmid":"21977277","id":"PMC_21977277","title":"HAS-1 genetic polymorphism in sporadic abdominal aortic aneurysm.","date":"2009","source":"Heart international","url":"https://pubmed.ncbi.nlm.nih.gov/21977277","citation_count":1,"is_preprint":false},{"pmid":"41695466","id":"PMC_41695466","title":"Therapeutic targeting of the AMPK-Has1 complex formation ameliorates metabolic dysfunction-associated steatohepatitis in mice.","date":"2026","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/41695466","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.29.626098","title":"4-Methyllumifrone (4-MU) can improve learning and memory after cerebral ischemia/reperfusion injury in rats","date":"2024-11-30","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.29.626098","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.12.637910","title":"Glucocorticoids modulate expression of perineuronal net component genes and parvalbumin during development of mouse cortical neurons","date":"2025-02-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.12.637910","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.05.636623","title":"Treatment of human oocytes with extracellular vesicles from follicular fluid during rescue in vitro maturation enhances maturation rates and modulates oocyte proteome and ultrastructure","date":"2025-02-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.05.636623","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.12.617979","title":"Critical role for the TGF-β1/mTORC1 signalling axis in defining the transcriptional identity of  <i>CTHRC1</i>  + pathologic fibroblasts","date":"2024-10-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.12.617979","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24576,"output_tokens":5010,"usd":0.074439,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13236,"output_tokens":2910,"usd":0.069465,"stage2_stop_reason":"end_turn"},"total_usd":0.143904,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"I need to carefully classify each paper before extracting. Key issue: \"Has1\" in yeast (papers 8, 27) refers to a DEAD-box RNA helicase involved in ribosome biogenesis — this is a completely different protein from human HAS1 (hyaluronan synthase 1). The yeast Has1 helicase is a symbol collision with the mammalian HAS1 hyaluronan synthase. I will exclude papers 8 and 27.\n\nPaper 16 is about sunflower (Helianthus annuus) asparagine synthetase genes — clear symbol collision, exclude.\n\nPapers 36, 37, 38, 39 are preprints — I'll evaluate if they add novel mechanistic content not covered by peer-reviewed work.\n\nNow extracting mechanistic discoveries from relevant papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"HAS1 protein alone is sufficient to synthesize hyaluronan in vitro from UDP-GlcNAc and UDP-GlcA substrates, and when incubated with UDP-GlcNAc alone synthesizes chito-oligosaccharides. Site-directed mutagenesis of the cytoplasmic central loop domain identified specific amino acid residues essential for hyaluronan synthesis (both GlcNAc and GlcA transfer steps) and separate residues exclusively required for GlcA transfer but dispensable for chito-oligosaccharide synthesis, demonstrating that distinct residues mediate each sugar transfer reaction.\",\n      \"method\": \"Recombinant FLAG-tagged HAS1 purification from COS-1 membranes by anti-FLAG affinity chromatography; in vitro enzymatic assay with UDP-sugars; site-directed mutagenesis of cytoplasmic central loop domain; reconstitutive assay conditions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted single-protein in vitro activity, combined with mutagenesis identifying catalytic residues in one rigorous study\",\n      \"pmids\": [\"10617644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HAS1 requires substantially higher cellular UDP-GlcNAc concentrations than HAS2 or HAS3 to synthesize hyaluronan. In COS-1 cells with normal UDP-sugar levels, HAS1 is nearly inactive; supplementing with glucosamine (~10-fold increase in UDP-GlcNAc) rescues HAS1-driven hyaluronan synthesis and pericellular coat formation. HAS3 can produce hyaluronan at high speed even at minimal substrate concentrations.\",\n      \"method\": \"Transfection of human HAS1-3 isoenzymes into COS-1 cells; glucosamine and glucose manipulation to alter UDP-sugar pools; measurement of secreted hyaluronan by ELISA; pericellular coat detection by fluorescent hyaluronan-binding probe; HPLC quantification of UDP-sugars\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (metabolic manipulation, HA quantification, UDP-sugar measurement) in single rigorous study with clear isoenzyme comparisons\",\n      \"pmids\": [\"23303191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HAS1, HAS2, and HAS3 form homomeric and heteromeric complexes with each other in live cells, detectable in both the Golgi apparatus and plasma membrane. Interactions occur primarily via an N-terminal ~86 amino acid domain, with additional C-terminal binding sites. HAS1 homomeric complexes have the lowest synthetic activity of all HAS complexes. HAS1 transfection reduces hyaluronan synthesis driven by HAS2 and HAS3, indicating that HAS1-containing heteromers functionally suppress overall HA synthesis.\",\n      \"method\": \"FRET with flow cytometric quantification in live cells; FRET microscopy with acceptor photobleaching; proximity ligation assay (PLA) with endogenous HAS antibodies; C-terminal deletion constructs to map interaction domains\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (FRET, PLA with endogenous proteins, deletion mapping, functional HA synthesis assay) in single study\",\n      \"pmids\": [\"25795779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HAS1-produced hyaluronan coat on MCF-7 cells depends on CD44 for retention at the cell surface (unlike HAS3, whose coat remains attached to HAS3 itself). HAS1 enzymatic activity requires ER-Golgi-plasma membrane trafficking. The HAS1-dependent coat is induced by inflammatory cytokines (IL-1β, TNF-α, TGF-β) and high glucose/glucosamine, revealing context-dependent activation.\",\n      \"method\": \"Immunocytochemistry; transfection of fluorescently tagged HAS1; fluorescent hyaluronan-binding probe for coat detection; displacement with HA hexasaccharides and Hermes1 (anti-CD44) antibody; cytokine and glucose/glucosamine treatments\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization and functional displacement experiments, single lab, two orthogonal approaches\",\n      \"pmids\": [\"24099991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HAS1 mRNA transcription in fibroblast-like synoviocytes is not constitutively active but is specifically induced by TGF-β and IL-1β. Hydrocortisone suppresses IL-1β-induced HAS1 activation by blocking TGF-β-induced phosphorylation of p38 MAPK, a kinase essential for HAS1 induction. HAS2 and HAS3 are constitutively expressed and are also suppressed by glucocorticoids, but via p38-independent mechanisms.\",\n      \"method\": \"RT-PCR for HAS mRNA levels in fibroblast-like synoviocytes; Western blot for p38 MAPK phosphorylation; glucocorticoid (hydrocortisone and dexamethasone) dose-response experiments\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Western blot for signaling pathway + mRNA quantification, single lab, two orthogonal methods\",\n      \"pmids\": [\"13130151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-1β induces HAS1 transcription via the NF-κB pathway (IκBα degradation and phosphorylation, NF-κB translocation), while TGF-β1 induces HAS1 transcription independently of NF-κB and IKK (TGF-β1 neither caused IκBα degradation nor NF-κB translocation). Overexpression of dominant-negative IKK or IκBα completely abolished IL-1β-induced HAS1 activation but did not affect TGF-β1-induced HAS1 or affect HAS2/HAS3 levels, demonstrating that HAS1 can be activated by two distinct upstream pathways.\",\n      \"method\": \"Adenovirus-mediated gene transfer of mutated IKK and IκBα constructs; RT-PCR for HAS mRNA; Western blot for IκBα phosphorylation/degradation; EMSA for NF-κB translocation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via dominant-negative constructs combined with multiple orthogonal methods (EMSA, Western blot, RT-PCR) establishing two independent pathway inputs to HAS1 transcription\",\n      \"pmids\": [\"16258173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-1β-induced HAS1 transcription in fibroblast-like synoviocytes depends on tyrosine kinase activity (not NF-κB alone): leflunomide specifically blocked IL-1β-induced HAS1 induction and HA synthase activity without affecting constitutive HAS2/HAS3 expression, and two tyrosine kinase inhibitors replicated this selective HAS1 blockade. NF-κB inhibition by leflunomide was ruled out as the mechanism at concentrations that block HAS1.\",\n      \"method\": \"RT-PCR for HAS mRNAs; 14C-glucuronic acid incorporation assay for HAS enzymatic activity; EMSA for NF-κB translocation; tyrosine kinase inhibitor treatment; pyrimidine rescue experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity assay combined with EMSA and pharmacological dissection, single lab\",\n      \"pmids\": [\"15905585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NF-κB is required for IL-1β-induced HAS1 transcription in type-B synoviocytes: the NF-κB inhibitor PDTC completely abolished IL-1β-induced HAS1 mRNA accumulation and simultaneously blocked IκBα degradation and NF-κB translocation. This confirms HAS1 as an NF-κB-dependent gene in this cell type.\",\n      \"method\": \"RT-PCR for HAS1 mRNA; Western blot for IκBα; EMSA for NF-κB DNA binding; PDTC dose-response treatment in type-B synoviocytes\",\n      \"journal\": \"Experimental gerontology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA, Western blot, and RT-PCR used together, single lab, corroborates the NF-κB dependence established by paper 16258173\",\n      \"pmids\": [\"16723203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Epstein-Barr virus and homopolymeric polycytidylic RNA analogs selectively induce HAS1 mRNA expression and HA release in fibroblast-like synoviocytes, while HAS2 and HAS3 remain unchanged. Virus-induced HAS1 activation requires both the p38 MAPK pathway and NF-κB: chemical MAPK inhibitors and overexpression of mutated IKK/IκBα each blocked virus-induced HAS1 transcription.\",\n      \"method\": \"Real-time RT-PCR; HA ELISA; chemical inhibitors of MAPK; adenovirus-mediated overexpression of mutated IKK and IκBα; treatment with live EBV and synthetic RNA polynucleotides\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (dominant-negative constructs) plus pharmacological dissection in single lab, consistent with prior mechanistic work\",\n      \"pmids\": [\"18815290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HAS1 splice variants (Va, Vb, Vc) are concentrated in the cytoplasm and Golgi, unlike full-length HAS1 (FL) which is diffusely distributed. HAS1 splice variants synthesize hyaluronan intracellularly. When co-expressed, HAS1 variants physically interact with HAS1-FL (and with each other) to form heteromeric multiprotein assemblies, relocalize HAS1-FL from diffuse cytoskeletal locations to deeper cytoplasmic compartments, and protect HAS1-FL from its otherwise rapid turnover. HAS1-Vc alone is transforming in vitro and tumorigenic in vivo.\",\n      \"method\": \"Co-transfection with fluorescently tagged constructs; immunofluorescence/confocal microscopy for localization; co-immunoprecipitation for protein–protein interactions; pulse-chase for protein turnover; in vitro transformation assay; in vivo xenograft tumor formation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, localization imaging, and functional assays (transformation, in vivo tumor), single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19451652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Genetic variations introduced into introns 3 and 4 of a HAS1 minigene promote aberrant pre-mRNA splicing (intron retention and exon skipping) mimicking the pattern seen in multiple myeloma patients. Combining intron 4 deletion with intron 3 mutations shifts splicing from HAS1Vd to HAS1Vb, the clinically significant variant. Most MM patients harbor genetic variations in intron 4, and ~half in intron 3, confirming that intronic mutations drive aberrant HAS1 splicing.\",\n      \"method\": \"HAS1 minigene constructs with introduced deletions/mutations; in vitro splicing assay; sequencing comparison of transfectants vs. MM patient samples\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro splicing assay with defined mutagenesis, validated against patient samples, single lab\",\n      \"pmids\": [\"23301075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Genetic deletion of Has1 in mice leads to chronic joint inflammation and widespread intra-articular fibrosis after cartilage injury, with persistent elevation of genes linked to ECM turnover, IL-17/IL-6 cytokine signaling, and apoptosis at 4 weeks post-injury (when wild-type mice show resolution). Notably, Has1 ablation does not alter gross HA content in ECM, indicating HAS1 has a unique function in regulating inflammatory HA matrices that is distinct from bulk HA production.\",\n      \"method\": \"Has1-/- mouse model; femoral groove cartilage debridement; histology, macroscopic imaging, and gene expression analysis at multiple timepoints; comparison with WT mice\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with specific phenotypic readout and gene expression profiling, single lab\",\n      \"pmids\": [\"26521733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Phosphorylated tau (p-tau) mediates AβPP-induced cytosolic-to-nuclear translocation of HAS1. p-tau negatively regulates HAS1 stability, monoubiquitination, and oligomerization, thereby reducing HA synthesis and release. Non-ubiquitinated HAS1 loses enzymatic activity and translocates into the nucleus where it forms nuclear speckles, suggesting a non-canonical nuclear function in gene transcription regulation.\",\n      \"method\": \"Transcriptomic database screening; AβPP/PS1 mouse model validation; immunofluorescence for HAS1 localization; co-localization with nuclear speckle markers (SRRM2); HAS1 ubiquitination mutant analysis; HA ELISA; transcriptomic analysis of DEGs related to non-ubiquitinated HAS1\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — abstract describes multiple findings but methods details are compressed; single lab, mechanistic chain (p-tau → HAS1 ubiquitination/localization) requires further validation\",\n      \"pmids\": [\"38518923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"STAT3 binds to the HAS1 promoter and positively regulates HAS1 expression; miR-125a suppresses STAT3 (a direct miR-125a target confirmed by dual-luciferase reporter), thereby reducing HAS1 mRNA and protein levels and suppressing NSCLC cell invasion and migration.\",\n      \"method\": \"Dual-luciferase reporter assay for miR-125a/STAT3 targeting; chromatin immunoprecipitation (ChIP) for STAT3 binding to HAS1 promoter; RT-qPCR and Western blot for STAT3 and HAS1; STAT3 overexpression; functional invasion/migration assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase assays are orthogonal methods establishing STAT3 as a direct transcriptional activator of HAS1, single lab\",\n      \"pmids\": [\"31930562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"HAS1 physically interacts with AMPK to form a complex, and disruption of this AMPK/HAS1 complex by elemicin ameliorates MASH. Loss-of-function of Has1 in liver reduces hepatic steatosis, inflammation, and fibrosis. Has1-mediated lipid metabolism is correlated with MASH severity.\",\n      \"method\": \"Co-immunoprecipitation (Co-IP); surface plasmon resonance (SPR); CETSA (cellular thermal shift assay); liver-specific Has1 inhibition in HFHC diet MASH mouse model; transcriptomic and lipidomic analyses; Western blotting\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, SPR, and CETSA for physical interaction, combined with in vivo loss-of-function, single lab\",\n      \"pmids\": [\"41695466\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HAS1 is a plasma membrane-resident hyaluronan synthase that alone is sufficient to polymerize hyaluronan from UDP-GlcNAc and UDP-GlcA, with distinct cytoplasmic central loop residues mediating each sugar-transfer reaction; it has the highest substrate Km among the three HAS isoenzymes and is nearly inactive at normal cellular UDP-GlcNAc levels, forms homo- and heteromeric complexes with HAS2 and HAS3 (suppressing overall HA synthesis when complexed), is transcriptionally activated by IL-1β via NF-κB and by TGF-β via an NF-κB-independent/tyrosine kinase-dependent pathway (both requiring p38 MAPK in viral contexts), produces a CD44-anchored pericellular HA coat induced by inflammatory cytokines and metabolic stress, and in cancer settings undergoes aberrant intronic splicing driven by somatic intron mutations that generate dominant variant proteins which relocalize and stabilize full-length HAS1, synthesize intracellular HA, and are oncogenic; additionally, HAS1 physically interacts with AMPK and, in an Alzheimer's disease context, undergoes p-tau-regulated monoubiquitination and nuclear translocation where it influences gene transcription.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HAS1 is a plasma membrane-resident hyaluronan synthase that polymerizes hyaluronan from UDP-GlcNAc and UDP-GlcA, and is alone sufficient for synthesis: reconstituted FLAG-tagged enzyme builds HA in vitro and, with UDP-GlcNAc only, chito-oligosaccharides, with distinct cytoplasmic central-loop residues mediating each sugar-transfer step [#0]. Among the three HAS isoenzymes it has the highest substrate requirement, being nearly inactive at normal UDP-GlcNAc levels and rescued only when the UDP-GlcNAc pool is raised by glucosamine [#1]. HAS1 assembles into homo- and heteromeric complexes with HAS2 and HAS3 via an N-terminal domain, and HAS1-containing complexes have the lowest synthetic output, so HAS1 functionally suppresses overall HA synthesis [#2]. Its enzymatic output requires ER-Golgi-plasma membrane trafficking and produces a CD44-anchored pericellular HA coat that is induced by inflammatory cytokines and high glucose/glucosamine [#3]. HAS1 is an inducible rather than constitutive gene, transcriptionally activated by IL-1\\u03b2 through an NF-\\u03baB- and tyrosine-kinase-dependent route and by TGF-\\u03b2 through an NF-\\u03baB-independent, p38 MAPK-dependent route [#4, #5], and is also a direct STAT3 target [#13]. In cancer, somatic intronic mutations drive aberrant HAS1 splicing into variants that relocalize and stabilize full-length HAS1, synthesize intracellular HA, and are oncogenic [#9, #10]. In vivo, Has1 loss causes chronic joint inflammation and intra-articular fibrosis without altering bulk ECM HA, indicating a specialized role in regulating inflammatory HA matrices [#11].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing whether HAS1 is itself the catalytic synthase resolved whether a single protein performs the full dual-sugar polymerization reaction.\",\n      \"evidence\": \"Purified recombinant FLAG-HAS1 in vitro enzymatic assay with UDP-sugars plus central-loop site-directed mutagenesis\",\n      \"pmids\": [\"10617644\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of the catalytic central loop\", \"Mechanism of processive chain elongation and membrane translocation not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Dissecting the upstream signaling inputs showed HAS1 is an inducible gene controlled by two independent transcriptional pathways rather than constitutive expression.\",\n      \"evidence\": \"Dominant-negative IKK/I\\u03baB\\u03b1 adenoviral epistasis, EMSA, RT-PCR, and tyrosine kinase inhibitor dissection in fibroblast-like synoviocytes (also #4, #6, #7, #8)\",\n      \"pmids\": [\"16258173\", \"13130151\", \"15905585\", \"16723203\", \"18815290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct NF-\\u03baB and TGF-\\u03b2-responsive elements in the HAS1 promoter not mapped\", \"How tyrosine kinase signaling converges on HAS1 transcription unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Characterizing HAS1 splice variants explained how aberrant HAS1 becomes oncogenic by relocalizing and stabilizing the full-length enzyme and producing intracellular HA.\",\n      \"evidence\": \"Co-transfection imaging, co-IP, pulse-chase turnover, in vitro transformation, and xenograft assays (also #10 minigene splicing)\",\n      \"pmids\": [\"19451652\", \"23301075\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Splicing factors driving the intronic-mutation-dependent shift not identified\", \"Mechanism by which intracellular HA promotes transformation unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Comparing isoenzyme kinetics and coat retention defined HAS1's distinctive low-activity, substrate-limited, CD44-dependent behavior relative to HAS2/HAS3.\",\n      \"evidence\": \"Isoenzyme transfection into COS-1 cells with UDP-sugar manipulation, HA ELISA, and CD44-antibody coat displacement (also #2 complex formation)\",\n      \"pmids\": [\"23303191\", \"24099991\", \"25795779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological conditions under which HAS1 reaches active UDP-GlcNAc thresholds in vivo unclear\", \"Structural basis for the suppressive effect of HAS1 heteromers not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Genetic ablation in mice separated HAS1's role in inflammatory HA matrices from bulk HA production.\",\n      \"evidence\": \"Has1-/- mice with cartilage injury, histology, and gene-expression profiling\",\n      \"pmids\": [\"26521733\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular source of the inflammatory HA matrix not pinpointed\", \"Link to IL-17/IL-6 signaling correlative, not mechanistic\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"An Alzheimer's-context study proposed a non-canonical nuclear function for HAS1 regulated by p-tau-dependent monoubiquitination.\",\n      \"evidence\": \"A\\u03b2PP/PS1 mouse validation, immunofluorescence, nuclear speckle co-localization, ubiquitination-mutant analysis, and HA ELISA\",\n      \"pmids\": [\"38518923\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Mechanistic chain (p-tau \\u2192 ubiquitination \\u2192 nuclear translocation) requires independent validation\", \"Direct transcriptional targets of nuclear HAS1 not established\", \"Ubiquitin ligase responsible unidentified\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identification of an AMPK/HAS1 complex implicated HAS1 in hepatic lipid metabolism and metabolic liver disease.\",\n      \"evidence\": \"Reciprocal Co-IP, SPR, CETSA, and liver-specific Has1 loss-of-function in an HFHC MASH mouse model\",\n      \"pmids\": [\"41695466\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How AMPK binding modulates HAS1 catalysis or vice versa unresolved\", \"Single lab; reciprocal in-cell consequence of complex disruption needs broader validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How HAS1's enzymatic activity, its suppressive heteromerization, and its non-canonical nuclear/metabolic functions are coordinated in a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model integrating catalysis, complex formation, and trafficking\", \"Physiological switch between membrane synthase and nuclear/regulatory roles unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [2, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"HAS2\", \"HAS3\", \"CD44\", \"AMPK\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}